Patents Issued in November 8, 2018
  • Publication number: 20180318416
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: June 11, 2018
    Publication date: November 8, 2018
    Applicant: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Publication number: 20180318417
    Abstract: Provided herein are multispecific immunomodulatory antigen-binding constructs (MIACs) and compositions comprising the constructs. Also provided are methods of using the constructs and methods of making the constructs.
    Type: Application
    Filed: January 13, 2016
    Publication date: November 8, 2018
    Inventors: Thomas Joseph SCHUETZ, Piotr BOBROWICZ, Helen SABZEVARI, Michael March SCHMIDT, Robert V. TIGHE, III, Simon METENOU
  • Publication number: 20180318418
    Abstract: The present invention relates to a new anti-BARF1 monoclonal antibody.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Inventors: Antonio ROSATO, Riccardo TURRINI, Riccardo DOLCETTI, Debora MARTORELLI, Damiana Antonia FAE
  • Publication number: 20180318419
    Abstract: The present invention provides methods and compositions for treating a cancer, methods for increasing an immune response against a tumor, methods for treating an autoimmune disease, and methods for decreasing an inflammation response in a subject in need thereof by modulating the expression and/or activity of Siglec 15 and/or its binding ligands.
    Type: Application
    Filed: November 9, 2016
    Publication date: November 8, 2018
    Inventors: Lieping CHEN, Jun WANG, Jingwei SUN
  • Publication number: 20180318420
    Abstract: A boron neutron capture therapy system has a neutron beam irradiation device, a patient restraint/placement portion, a three-dimensional diagnostic device, an irradiation table, a position adjustment mechanism, and a control unit. The boron neutron capture therapy system performs position determination with a sufficient degree of accuracy at the time of the boron neutron capture therapy. Further, the control unit, using the movement of the irradiation table, performs collision avoidance processing that changes the movement of the irradiation table before the patient restrained on the patient restraint/placement portion receives injury by colliding with the irradiation port, and thus, collision between the patient and the irradiation port can be avoided.
    Type: Application
    Filed: July 19, 2018
    Publication date: November 8, 2018
    Inventors: Tsuyako TAKEYOSHI, Masaru NAKAMURA, Yoshio IMAHORI, Hideki MIYAZAKI, Toshitaka FUJIOKA, Shinsuke KATO
  • Publication number: 20180318421
    Abstract: Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 8, 2018
    Inventor: Stanislaw R. Burzynski
  • Publication number: 20180318422
    Abstract: The present invention provides a method for suppressing bitterness of a quinoline derivative.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 8, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Kentaro Nagane, Yosuke Ueki, Shusuke Sano, Takahisa Sakaguchi
  • Publication number: 20180318423
    Abstract: Self-assembled gel compositions including a gelator, e.g., an enzyme-cleavable gelator, e.g., having a molecular weight of 2500 or less, are described. The self-assembled gel compositions can encapsulate one or more agents. Methods of making the self-assembled gel compositions, and methods of drug delivery using the self-assembled gel compositions are also described.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 8, 2018
    Inventors: Jeffrey M. Karp, Praveen Kumar Vemula, Nathaniel R. Campbell, Abdullah M. Syed, Sufeng Zhang, Omid C. Farokhzad, Robert S. Langer
  • Publication number: 20180318424
    Abstract: A nanostructure coated with a twist-strained double-stranded circular deoxyribonucleic acid (DNA) is provided, together with methods for preparing the coated nanostructure, for removing the DNA coating from the nanostructure, and for sorting nanostructures using the DNA coating.
    Type: Application
    Filed: July 12, 2017
    Publication date: November 8, 2018
    Inventor: Sonia Trigueros
  • Publication number: 20180318425
    Abstract: The present invention provides compositions and methods for providing controllable local delivery of a conjugate of bortezomib (Btz) and a bisphosphonate to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Inventors: Frank Ebetino, Robert Boeckman, Lianping Xing, Lifeng Xiao, Brendan Boyce
  • Publication number: 20180318426
    Abstract: Disclosed is a pharmaceutical formulation comprising an insulin or insulin analog molecule covalently attached to at least one branched linker having a first arm and second arm, wherein the first arm is linked to a first ligand that includes a first saccharide and the second arm is linked to a second ligand that includes a second saccharide and wherein the first saccharide is fucose. The formulation is suitable for subcutaneous administration and provides a basal pharmacodynamic profile for the insulin oligosaccharide conjugate.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 8, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Shuai Shi, Valentyn Antochshuk, Joseph Rizzo, Niels C. Kaarsholm
  • Publication number: 20180318427
    Abstract: Disclosed is a pharmaceutical formulation comprising an insulin or insulin analog molecule covalently attached to at least one branched linker having a first arm and second arm, wherein the first arm is linked to a first ligand that includes a first saccharide and the second arm is linked to a second ligand that includes a second saccharide and wherein the first saccharide is fucose suitable for parenteral or subcutaneous administration and which is suitable for use in controlling post-prandial glucose levels in an individual.
    Type: Application
    Filed: April 30, 2018
    Publication date: November 8, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Shuai Shi, Valentyn Antochshuk, Joseph Rizzo
  • Publication number: 20180318428
    Abstract: Polymers useful for associating therewith oligonucleotides and for delivering the oligonucleotides into a cell, conjugates comprising these polymers and an oligonucleotide associated therewith, and compositions comprising same are provided. Also provided are uses of these conjugates in, for example, gene therapy, and particularly gene silencing. The disclosed polymers feature a PGA backbone, and amine-terminated pendant groups attached to at least 40% of the backbone units, and optionally further comprise alkyl pendant groups and/or other nitrogen-containing pendant groups attached to other one or more portions of the backbone units. The disclosed polymers can be cross-linked or can form a part of a block-copolymer.
    Type: Application
    Filed: September 30, 2016
    Publication date: November 8, 2018
    Inventors: Ronit SATCHI-FAINARO, Anna SCOMPARIN, Dina POLYAK, Adva KRIVITSKY, Shay ELIYAHU, Hadas GIBORI
  • Publication number: 20180318429
    Abstract: Examples may include a method of making a protein-PEG conjugate salt with increased hydrophobicity. The method may include providing an aqueous protein solution. This aqueous protein solution may include a protein and a pH buffer. The method may also include reacting a polyethylene glycol with the protein to form a protein-PEG conjugate. The method may further include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid in an organic phase. The protonation may form the protein-PEG conjugate salt having a hydrophobic anion that increases the hydrophobicity-PEG conjugate salt.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Applicant: Rezolute, Inc.
    Inventors: Mary S. Rosendahl, Sankaram B. Mantripragada, Eliana B. Gomez
  • Publication number: 20180318430
    Abstract: Provided is a composition comprising an RNAi molecule which suppresses expression of CHST15 gene and successfully used for less invasive administration.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Applicant: STILIC INSTITUTE & CO., INC.
    Inventor: Hiroyuki YONEYAMA
  • Publication number: 20180318431
    Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
    Type: Application
    Filed: December 8, 2016
    Publication date: November 8, 2018
    Inventors: Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson
  • Publication number: 20180318432
    Abstract: The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.
    Type: Application
    Filed: July 11, 2018
    Publication date: November 8, 2018
    Inventors: Juergen Siekmann, Alfred Weber, Hanspeter Rottensteiner, Peter Turecek
  • Publication number: 20180318433
    Abstract: The present invention pertains to a composition comprising at least one biocompatible and biodegradable polymer, said polymer further comprising nanocarriers wherein said nanocarriers comprise a drug. Moreover, also encompassed by the invention is the use of said composition in the treatment of a disease and a method for manufacturing said composition.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Matthias WACKER, Susanne BEYER, Michael PARNHAM, Werner MÄNTELE, Li XIE, Vitali VOGEL
  • Publication number: 20180318434
    Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 8, 2018
    Inventors: Gregory Lawrence Verdine, M. James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
  • Publication number: 20180318435
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.
    Type: Application
    Filed: November 10, 2016
    Publication date: November 8, 2018
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Service, Sanford Research
    Inventors: Ira H. Pastan, Tapan Bera, Satoshi Nagata, Tomoko Ise, Yasuhiro Abe
  • Publication number: 20180318436
    Abstract: The present invention relates to a method for inducing an immune response manifested by type I interferon production in a synergistic manner comprising the sequential administration of danger signals within a certain timeframe and means for practicing the method. The present invention is particularly useful for immunomodulation, immunotherapy and vaccination.
    Type: Application
    Filed: October 20, 2016
    Publication date: November 8, 2018
    Inventor: Steve PASCOLO
  • Publication number: 20180318437
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: November 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO-GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Dennis KIRCHHOFF
  • Publication number: 20180318438
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: November 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Stephan MÄRSCH, Uwe GRITZAN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT, Lisa DIETZ
  • Publication number: 20180318439
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Application
    Filed: July 25, 2018
    Publication date: November 8, 2018
    Applicants: Immunomedics, Inc., Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Publication number: 20180318440
    Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
    Type: Application
    Filed: September 19, 2016
    Publication date: November 8, 2018
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Javed Khan, Sivasubramanian Baskar, Rimas J. Orentas, Dimiter S. Dimitrov, Zhongyu Zhu
  • Publication number: 20180318441
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Application
    Filed: April 5, 2018
    Publication date: November 8, 2018
    Applicants: ABBVIE STEMCENTRX LLC, MEDIMMUNE LIMITED
    Inventors: Michael TORGOV, Philip Wilson HOWARD
  • Publication number: 20180318442
    Abstract: A gel formulation has been developed which provides high loading, e.g., between about 5% and about 50% wt/wt agent/total gel weight, of a wide range of agents, especially amine-containing compounds such as local anesthetic agents that are known to be difficult to encapsulate, and which adhere to charged surfaces. Examples of pharmaceutically important amines include anesthetics, such as lidocaine. Tuning the ionic strength of an aqueous medium during preparation, suspension, and dialysis purification of the hydrogel composition allows for retention and/or control of agent loading contents, as well as a high capacity for adhesion to charged surfaces mimicking inflamed tissue. In some instances, the rheological properties of the gel can be tuned such as to impart thixotropic properties to the gels formed.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 8, 2018
    Inventors: Derek G. van der Poll, Dominick J. Blasioli, Gregory T. Zugates
  • Publication number: 20180318443
    Abstract: A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.
    Type: Application
    Filed: December 5, 2017
    Publication date: November 8, 2018
    Inventors: Anirban Sen Gupta, Madhumitha Ravikumar, Christa Modery
  • Publication number: 20180318444
    Abstract: The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the
    Type: Application
    Filed: November 8, 2016
    Publication date: November 8, 2018
    Inventors: John M. MARIS, Kristopher R. BOSSE, Dimiter DIMITROV, Zhongyu ZHU
  • Publication number: 20180318445
    Abstract: The present application provides an amphiphilic cyclodextrin-based compound of the formula I: R-G-D-A (I) wherein R is one or more hydrophilic groups; G is one or more linkers; D is a cyclodextrin, and A is one or more aliphatic groups. In cer-tain embodiments, the hydrophilic group is a sugar such as lactose, the linker comprises —(CHR?CH20)n- where R? is H or is an alkyl group substituted with —(CHR?CH20)n- where n is 1 to 20, typically n=4; the cyclodextrin is a B-cyclodextrin comprising 7 subunits, and the aliphatic groups are C6 alkyl groups. The compound can be used to enhance water solu-bility, bioavailability, cellular uptakes of active ingredients used in medicines, cosmetics and foods and other products, for detection, removal and immobilization of pathogenic organisms, toxins, and autoantibodies, and bio-markers on solid matrix, or for molecular biological techniques, such as ELISA, for example.
    Type: Application
    Filed: March 23, 2018
    Publication date: November 8, 2018
    Inventors: Chang-Chun Ling, Lina Cui, Ramprasad Ghosh, Ping Zhang, Aixia Yan Wang
  • Publication number: 20180318446
    Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of viruses. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent viral infection, or to improve a subject's heath or wellbeing.
    Type: Application
    Filed: February 26, 2018
    Publication date: November 8, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Stephane Bancel, Jason P. Schrum, Alexander Aristarkhov
  • Publication number: 20180318447
    Abstract: The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.
    Type: Application
    Filed: November 30, 2016
    Publication date: November 8, 2018
    Inventors: Saliha MAJDOUL, David FENARD
  • Publication number: 20180318448
    Abstract: An object of the present invention is to provide a method for determining whether a subject suffers from malignant lymphoma or leukemia and an agent for treating and/or preventing the disease. The present invention relates to a method for assisting in determining whether a subject suffers from, or is likely to suffer from malignant lymphoma or leukemia, comprising: a detection step of detecting at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene; and a determination step of determining that the subject suffers from or is likely to suffer from the disease when at least one of the fusion mutations or the overexpression is detected. Moreover, the present invention relates to a pharmaceutical composition comprising a DUX4 inhibitor as an active ingredient, for treating and/or preventing malignant lymphoma or leukemia in a subject having a fusion mutation of a DUX4 gene and an IGH or IGL gene and/or overexpression of a DUX4 gene.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 8, 2018
    Inventors: Hiroyuki MANO, Toshihide UENO, Takahiko YASUDA, Masahito KAWAZU, Fumihiko HAYAKAWA, Hitoshi KIYOI, Shinobu TSUZUKI, Tomoki NAOE
  • Publication number: 20180318449
    Abstract: Isolated polynucleotides comprising an OLIG1 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, guide RNA, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.
    Type: Application
    Filed: May 2, 2018
    Publication date: November 8, 2018
    Inventors: Elizabeth M. Simpson, Charles de Leeuw, Wyeth W. Wasserman, Daniel Goldowitz
  • Publication number: 20180318450
    Abstract: The various embodiments relate to the identification of non-viable tissue for debridement using a ph low insertion peptide conjugate. ph low insertion peptide conjugates are described having fluorescent dye for introduction to the wound area. The peptides may further be conjugated with a drug for introduction to the tissue.
    Type: Application
    Filed: May 2, 2018
    Publication date: November 8, 2018
    Inventors: Jonathan W. BOYD, Matthew LOOS
  • Publication number: 20180318451
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Application
    Filed: July 6, 2016
    Publication date: November 8, 2018
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.
    Inventors: Arne SKERRA, Antonia RICHTER, Volker MORATH, Cyril BARINKA, Jakub PTACEK
  • Publication number: 20180318452
    Abstract: A fluorescent solution is disclosed for use in a hydraulic or diesel fluid to facilitate detection of injection of the hydraulic of diesel fluid into a human. The fluorescent solution includes a fluorescent dye and a stabilizing agent. The stabilizing agent may be a surfactant. A hydraulic fluid mixture is also disclosed which includes a fluorescent solution and a hydraulic fluid.
    Type: Application
    Filed: April 2, 2018
    Publication date: November 8, 2018
    Applicant: Quaker Chemical (Australasia) Pty Ltd
    Inventor: Wayne Thompson
  • Publication number: 20180318453
    Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
    Type: Application
    Filed: May 12, 2016
    Publication date: November 8, 2018
    Inventors: Richard B. Dorshow, Thomas E. Rogers
  • Publication number: 20180318454
    Abstract: Disclosed herein are polycationic polymers and methods of using the same. The polycationic polymer comprises a dendrimer or dendron, the dendrimer or the dendron comprising a focal point, a plurality of cationic termini, and a branched cationic polymer between the focal point and the plurality of cationic termini. Also disclosed polycationic polymers further comprising a detectable label; and a crosslinker, wherein the crosslinker links the detectable label and the focal point of the dendron. The resulting conjugated polycationic polymers may be used in tracking methods of methods of treating disease. Methods of using polycationic polymers to treat autoimmune diseases, infectious diseases and acute radiation syndrome are also disclosed.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Applicant: Duke University
    Inventors: Bruce A. Sullenger, Hemraj Juwarker, Angelo Moreno, Nelson Chao, Eda Holl
  • Publication number: 20180318455
    Abstract: The invention relates to a complex between block polymers comprising a first hydrophilic block and a second block comprising at least one ionised function, and optionally carrying at least one additional chemical or biochemical group or comprising a third polymer block, and mixtures of said polymers, and ions selected from the elements Cu, Ga, Sr, Bi, Se, Y, lanthanide, Pb, Te, Zn, Zr at different degrees of ionisation and the mixtures thereof, more particularly for the use thereof in medical imaging, and to a production method and a physiologically acceptable composition containing said complex.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ), UNIVERSITE PAUL SABATIER TOULOUSE III
    Inventors: Christophe MINGOTAUD, Jean-Daniel MARTY, Camille FRANGVILLE, Daniel THALHAM
  • Publication number: 20180318456
    Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
    Type: Application
    Filed: January 31, 2018
    Publication date: November 8, 2018
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Heike S. Radeke, Suresh K. Pandey, Ajay Purohit, Simon P. Robinson
  • Publication number: 20180318457
    Abstract: This disclosure relates to a device for disinfecting CPAP components and a method of using the same. An example device includes a chamber, an ultraviolet (UV) light configured to emit UV light within the chamber, and a control unit configured to activate the UV light for a period of time.
    Type: Application
    Filed: April 19, 2018
    Publication date: November 8, 2018
    Inventor: Albert A. Lucio
  • Publication number: 20180318458
    Abstract: The invention relates to a facility which has a dirty facility area and an adjacent clean facility area, baskets for receiving the dirty articles, and a wall separating the dirty area from the clean area, the dirty area including an entry door for receiving the dirty articles, pre-processing stations with tables for the pre-washing and/or sorting by a human operator, or even by a robotic operator, of the dirty articles and for arranging the pre-washed and/or sorted articles in the baskets, pick-up points at the pre-processing stations for pick-up of the baskets with the pre-washed and/or sorted articles, a plurality of washers, eg.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Inventor: Kim RASMUSSEN
  • Publication number: 20180318459
    Abstract: Sterilization apparatus comprising a sterilization instrument configured to be inserted through the instrument channel of a surgical scoping device and a withdrawal device for withdrawing the sterilization instrument from the instrument channel at a predetermined rate. The sterilization instrument comprises an elongate probe having a probe tip with a first electrode and a second electrode arranged to produce an electric field from received RF and/or microwave frequency EM energy. In operation the instrument may disinfect an inner surface of the instrument channel by emitting energy whilst being withdrawn through the channel.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 8, 2018
    Inventors: Christopher Paul HANCOCK, Louis TURNER, Patrick BURN, Sandra SWAIN, Mark EBBUTT, Simon MEADOWCROFT, George Christian ULLRICH, David Edward WEBB, John BISHOP
  • Publication number: 20180318460
    Abstract: An emitter including a charcoal composition, a flat base section disposed on a bottom portion of the charcoal composition, a scented configuration piece is configured to be operable for emitting a scented smell when burned, a belly segment disposed at a proximate inner chamber of the charcoal composition, and wherein the belly segment is configured to accept said scented configuration piece. A top or side portion opening leads to the belly segment and scent of the burning scented configuration piece disburses out of a mouth portion disposed on a proximate top portion of the charcoal composition.
    Type: Application
    Filed: May 6, 2018
    Publication date: November 8, 2018
    Inventor: Abdulkadir Hashi Ali
  • Publication number: 20180318461
    Abstract: Disclosed herein is a scent-emanating apparatus including a discharging mechanism which permits a scent substance perceivable by a user together with a marker substance for detection to be discharged outwards, and a sensor to detect the marker substance discharged from the discharging mechanism.
    Type: Application
    Filed: July 29, 2016
    Publication date: November 8, 2018
    Inventors: Yoichi NISHIMAKI, Shinichi HIRATA, Yuichi MACHIDA, Kazuo MIURA
  • Publication number: 20180318462
    Abstract: A scent diffuser (e.g., air freshener) configured to automatically circulate fragrant air throughout a surrounding environment comprises a powered air circulator configured for circulating air and a fragrance composition throughout the surrounding environment, and a solar cell positioned within a support face of the air circulator. The support face is configured to secure the scent diffuser relative to a support surface and has an open portion configured to allow light to contact the solar cell. The air circulator may comprise a centrifugal fan positioned within the housing and configured to draw air through intake apertures in sidewalls of the housing and to exhaust air and fragrance through an outflow aperture of the housing.
    Type: Application
    Filed: May 3, 2017
    Publication date: November 8, 2018
    Inventors: Chris Bourne, Kathy Rasmussen
  • Publication number: 20180318463
    Abstract: A method for intraoperatively measuring joint contact mechanics of a patient's joint is provided. The method includes inserting a sensor between first and second bones of a joint. Then a predetermined force is applied to one of the first and second bones. Afterwards, contact mechanics such as, contact stresses, contact areas and/or forces are measured between the first and second bones in response to the applied predetermined force.
    Type: Application
    Filed: June 29, 2018
    Publication date: November 8, 2018
    Applicant: Hospital for Special Surgery
    Inventors: Suzanne Maher, Scott Rodeo, Russell Warren, Hongsheng Wang, Mario Lustri
  • Publication number: 20180318464
    Abstract: An intraocular lens material disclosed in the present description includes an aromatic ring-containing acrylate structural unit, an alkoxyalkyl methacrylate structural unit including an alkoxy group having 4 or less carbon atoms, a hydrophilic structural unit based on a hydrophilic monomer, and a cross-linking structural unit based on a cross-linkable monomer.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 8, 2018
    Applicant: MENICON CO., LTD
    Inventors: Yuya SUGANUMA, Hiroko NOMURA, Tatsuya OJIO
  • Publication number: 20180318465
    Abstract: The present invention relates to a novel bone graft and methods for producing said graft. Said bone graft can be used for surgical, plastic and/or cosmetic bone replacement for a patient in need thereof. The bone graft is made of a scaffold or matrix of sheet material having a 3-dimensional pattern of a continuous network of voids and/or indentations for enhancing new bone growth.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventor: Timothy Ganey